- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.
Adam Cuker - "Monitoring unfractionated heparin: best practices and controversies"
Dr. Cuker willreview evidence, controversies, and best practices in the measurement and monitoring of unfractionated heparin, low molecular weight heparin, and fondaparinux.
Gualtiero Palareti - "Monitoring of direct oral anticoagulants"
Dr. Palareti will review in which circumstances and for which purposes measuring the concentration of the direct oral anticoagulants (DOACs) is indicated and which are the laboratory assays that should be used for this scope and those that are not recommended.
Moderator: Geoff Barnes
Dr. Cuker is Assistant Professor of Medicine and Pathology & Laboratory Medicine at the University of Pennsylvania. He received his M.D. from Yale University and completed an internship and residency in internal medicine at Brigham and Women’s Hospital and Harvard Medical School. He continued his postgraduate training at the Hospital of the University of Pennsylvania where he was a fellow in hematology/oncology. He holds a Master’s degree in Translational Research from the University of Pennsylvania. He is Director of the Penn Comprehensive Hemophilia & Thrombosis Program, Clinical Director of the Penn Blood Disorders Center, and Associate Director for Clinical Research of the Penn-CHOP Blood Center for Patient Care and Discovery. Major focuses of his research include laboratory measurement of anticoagulation, heparin-induced thrombocytopenia, and immune thrombocytopenia. He is Chair of the forthcoming American Society of Hematology guidelines on venous thromboembolism; serves on the Board of Directors of the Hemostasis & Thrombosis Research Society and the Anticoagulation Forum; is a fellow of the American College of Physicians; and a member of ISTH.
Dr. Palareti is a Professor of Cardiovascular Diseases at the University of Bologna, Italy. He is a co-Founder and former President of the Italian Federation of Anticoagulation Clinics (FCSA). From 2004-2012 he served as aCo-Chairman of the SSC Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis (ISTH). He is also a former President of theItalian Society for Hemostasis and Thrombosis (SISET).
Dr. Barnes is a cardiologist and vascular medicine specialist at the University of Michigan in Ann Arbor, Michigan, USA. His research interests include quality improvement in anticoagulation and the used of shared decision making tools for venous thromboembolism. He currently serves as the immediate past chair of the ISTH Young Professional Task Force and serves on the ISTH Education committee.
Sponsored by an unrestricted educational grant from: Instrumentation Laboratory
Clinicaians and laboratory professional involved in the management of patients on anticoagulant therapy
At the conclusion of this activity, I will be able to:
- Understand the evidence for and against laboratory monitoring of unfractionated heparin.
- Identify indications for measurement of low molecular weight heparin and fondaparinux.
- Describe current best practices for monitoring and measurement of unfractionated heparin, low molecular weight heparin, and fondaparinux.
- Understand the difference between monitoring and measuring anticoagulant agents
- Learn in which circumstances measuring the concentration of DOACs can help clinical management decisions
- Understand which are the assays that are recommended to measure the effect of dabigatran, rivaroxaban, apixaban and edoxaban
- Understand which are the limitations of routine coagulation assays for this scope and why their use is not recommended to measure the anticoagulant effect of DOACs
- Understand which are the specific effects of DOACs on tests of hemostasis
Dr. Adam Cuker will review evidence, controversies, and best practices in the measurement and monitoring of unfractionated heparin, low molecular weight heparin, and fondaparinux.
Gualtiero Palareti "Monitoring of direct oral anticoagulants"
Dr. Gualtiero Palareti will review in which circumstances and for which purposes measuring the concentration of the direct oral anticoagulants (DOACs) is indicated and which are the laboratory assays that should be used for this scope and those that are not recommended.
|Geoffrey Barnes, MD||Portola||Consulting|
|Blue Cross Blue Shield of Michigan||Research|
|Chris Ward, PhD||Bayer||Speaker|
|Boehringer-Ingelheim||Speaker, Advisory Board|
|BMS/Pfizer||Speaker, Advisory Board|
|Adam Cuker, MD||Amgen||Consultant|
|Bracco Diagnostic Imaging||Consultant|
|Gualtiero Palareti, MD||Alfa-Wassermann||Advisory Board|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved